This month NETRF CEO Elyse Gellerman presented on behalf of INCA at the ASCO Quality Care Symposium in Boston. NETRF is a member of INCA,
By Anne-Marie Green Director of Communications, NETRF Erik Mittra, MD, PhD, is the Section Chief of Molecular Imaging and Therapy at Oregon Health & Science
By Anna C. Greene, PhD, NETRF Chief Scientific Officer Research is helping physicians make more informed decisions about how to treat and monitor neuroendocrine cancers.
By Anna C. Greene, PhD, NETRF Chief Scientific Officer Scientific progress rarely comes from a single experiment, or even a single research grant. It happens
When chemotherapy stops working, patients and their care teams are left with few options. For people with poorly differentiated neuroendocrine carcinoma, that moment comes too
Elyse Gellerman, MHS, NETRF CEO When neuroendocrine cancer advocates from around the world gather, there’s tremendous energy and commitment to serving the needs of patients
By Anna C. Greene, PhD, NETRF Chief Scientific Officer The language used to describe neuroendocrine cancer is complex, and it is not always used consistently.
The FDA has approved lutetium Lu-177 dotatate injection (Bexlutry), a new option for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Bexlutry is a radioligand
CDH17 Remains a Promising Target, Even as the CHM CDH17 Trial Changes Course The CHM CDH17 clinical trial, a CAR T-cell therapy built on research
By Anna C. Greene, PhD, NETRF Chief Scientific Officer Same organ, different disease Words matter in cancer, especially when the name of an organ becomes